Skip to content

Study · Randomized controlled trial · n = 10 · 2000

5 results

The GH response to low-dose bolus growth hormone-releasing hormone (GHRH(1-29)NH2) is attenuated in patients with longstanding post-irradiation GH insufficiency.

Achermann JC, Brook CG, Hindmarsh PC

European journal of endocrinology1 Apr 2000Cited by 9 (Europe PMC)

PMID10754477 (opens in a new tab)DOI10.1530/eje.0.1420359 (opens in a new tab)PepBankPUB-10754477
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialActivity measurement

    In irradiated subjects, GH output rose step by step with increasing GHRH(1-29)NH2 doses, reflecting altered pituitary sensitivity and reduced responsiveness.

    In plain wordsIn irradiated adults, GH release rose with each higher GHRH dose, which points to reduced pituitary responsiveness.

    Peptide
    Sermorelin
    Outcome
    IncreaseGH output across GHRH doses in irradiated subjects
    Study

    n = 5

    Comparator
    Lower GHRH doses
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.05, 0.15 and 1.0 μg/kg · intravenous bolus · single bolusAs given in this study (human).

    Measurements

    Median GH AUC
    122 mU/l.min
    irradiated, lowest dose
    Median GH AUC
    179 mU/l.min
    irradiated, middle dose
    Median GH AUC
    268 mU/l.min
    irradiated, highest dose

    Source sentences

    Summary
    In irradiated subjects there was an incremental rise in GH output with increasing doses of GHRH(1-29)NH(2 )(median AUC: 122mU/l.min vs 179mU/l.min vs 268mU/l.min; P=0.007) reflecting altered pituitary sensitivity and reduced responsiveness.
    1 context sentence
    Summary · context
    Five adult male long-term survivors of childhood brain tumours (median age 21.8 years (18.4-26.7); 13.7 years (11.4-15.7) post-radiotherapy, >30Gy) and five matched controls were studied.
  2. 02HumanObservational studyActivity measurement

    In long-term survivors of childhood brain tumours after cranial irradiation, peak GH after 0.15 μg/kg GHRH(1-29)NH2 was significantly lower than in matched controls.

    In plain wordsIn adults irradiated for childhood brain tumours, the GH peak after a low GHRH dose was lower than in matched controls.

    Peptide
    Sermorelin
    Outcome
    DecreasePeak GH after 0.15 μg/kg GHRH(1-29)NH2
    Study

    n = 10

    Comparator
    Matched controls
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.15 μg/kg · intravenous bolus · single bolusAs given in this study (human).

    Measurements

    Median peak GH
    37.4 mU/l
    controls, 0.15 μg/kg

    Source sentences

    Summary
    Significantly lower peak and area under the curve (AUC) GH concentrations occurred in the irradiated group using 0.15 microg/kg (median peak Irradiated, 4. 5mU/l vs median Controls, 37.4mU/l; P<0.01) and 1.0 microg/kg (median peak Irradiated, 4.8mU/l vs median Controls, 15.2mU/l; P<0. 05) GHRH(1-29)NH(2).
    1 context sentence
    Summary · context
    Five adult male long-term survivors of childhood brain tumours (median age 21.8 years (18.4-26.7); 13.7 years (11.4-15.7) post-radiotherapy, >30Gy) and five matched controls were studied.
  3. 03HumanObservational studyActivity measurement

    In long-term survivors of childhood brain tumours after cranial irradiation, GH area under the curve after 0.15 μg/kg GHRH(1-29)NH2 was significantly lower than in matched controls.

    In plain wordsIn adults irradiated for childhood brain tumours, total GH release after a low GHRH dose was lower than in matched controls.

    Peptide
    Sermorelin
    Outcome
    DecreaseGH AUC after 0.15 μg/kg GHRH(1-29)NH2
    Study

    n = 10

    Comparator
    Matched controls
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    0.15 μg/kg · intravenous bolus · single bolusAs given in this study (human).

    Source sentences

    Summary
    Significantly lower peak and area under the curve (AUC) GH concentrations occurred in the irradiated group using 0.15 microg/kg (median peak Irradiated, 4. 5mU/l vs median Controls, 37.4mU/l; P<0.01) and 1.0 microg/kg (median peak Irradiated, 4.8mU/l vs median Controls, 15.2mU/l; P<0. 05) GHRH(1-29)NH(2).
    1 context sentence
    Summary · context
    Five adult male long-term survivors of childhood brain tumours (median age 21.8 years (18.4-26.7); 13.7 years (11.4-15.7) post-radiotherapy, >30Gy) and five matched controls were studied.
  4. 04HumanObservational studyActivity measurement

    In long-term survivors of childhood brain tumours after cranial irradiation, peak GH after 1.0 μg/kg GHRH(1-29)NH2 was significantly lower than in matched controls.

    In plain wordsIn adults irradiated for childhood brain tumours, the GH peak after a high GHRH dose was lower than in matched controls.

    Peptide
    Sermorelin
    Outcome
    DecreasePeak GH after 1.0 μg/kg GHRH(1-29)NH2
    Study

    n = 10

    Comparator
    Matched controls
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1.0 μg/kg · intravenous bolus · single bolusAs given in this study (human).

    Measurements

    Median peak GH
    4.8 mU/l
    irradiated, 1.0 μg/kg
    Median peak GH
    15.2 mU/l
    controls, 1.0 μg/kg

    Source sentences

    Summary
    Significantly lower peak and area under the curve (AUC) GH concentrations occurred in the irradiated group using 0.15 microg/kg (median peak Irradiated, 4. 5mU/l vs median Controls, 37.4mU/l; P<0.01) and 1.0 microg/kg (median peak Irradiated, 4.8mU/l vs median Controls, 15.2mU/l; P<0. 05) GHRH(1-29)NH(2).
    1 context sentence
    Summary · context
    Five adult male long-term survivors of childhood brain tumours (median age 21.8 years (18.4-26.7); 13.7 years (11.4-15.7) post-radiotherapy, >30Gy) and five matched controls were studied.
  5. 05HumanObservational studyActivity measurement

    In long-term survivors of childhood brain tumours after cranial irradiation, GH area under the curve after 1.0 μg/kg GHRH(1-29)NH2 was significantly lower than in matched controls.

    In plain wordsIn adults irradiated for childhood brain tumours, total GH release after a high GHRH dose was lower than in matched controls.

    Peptide
    Sermorelin
    Outcome
    DecreaseGH AUC after 1.0 μg/kg GHRH(1-29)NH2
    Study

    n = 10

    Comparator
    Matched controls
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1.0 μg/kg · intravenous bolus · single bolusAs given in this study (human).

    Source sentences

    Summary
    Significantly lower peak and area under the curve (AUC) GH concentrations occurred in the irradiated group using 0.15 microg/kg (median peak Irradiated, 4. 5mU/l vs median Controls, 37.4mU/l; P<0.01) and 1.0 microg/kg (median peak Irradiated, 4.8mU/l vs median Controls, 15.2mU/l; P<0. 05) GHRH(1-29)NH(2).
    1 context sentence
    Summary · context
    Five adult male long-term survivors of childhood brain tumours (median age 21.8 years (18.4-26.7); 13.7 years (11.4-15.7) post-radiotherapy, >30Gy) and five matched controls were studied.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.